|
|
|
|
Sucampo Pharmaceuticals Selected As A Finalist For Scrip Awards 2008 Pharma Company Of The Year - Small And Me
Sucampo Pharmaceuticals, Inc.(NASDAQ:SCMP), a leading international biopharmaceutical company, today announced that it has been selected as a finalist for the Scrip Awards 2008 Pharma Company of the Year -- Small and Medium-Sized...
|
|
|
Sucampo Pharmaceuticals Selected as a Finalist for Scrip Awards 2008 Pharma Company of the Year EUR Small and
- Sucampo Pharmaceuticals, Inc.(NASDAQ:SCMP), a leading international biopharmaceutical company, today announced that it has been selected as a finalist for the Scrip Awards 2008 Pharma Company of the Year Small and Medium-Sized...
|
|
|
Sucampo Pharmaceuticals Selected as a Finalist for Scrip Awards 2008 Pharma Company of the Year Small and Medi
BETHESDA, MD (Business Wire) -- Sucampo Pharmaceuticals, Inc.(NASDAQ:SCMP), a leading international biopharmaceutical company, today announced that it has been selected as a finalist for the Scrip Awards 2008 Pharma Company of the Year --...
|
|
|
Sucampo Pharmaceuticals Selected as a Finalist for Scrip Awards 2008 Pharma Company of the Year
Sucampo Pharmaceuticals, Inc.(NASDAQ:SCMP), a leading international biopharmaceutical company, today announced that it has been selected as a finalist for the Scrip Awards 2008 Pharma Company of the Year -- Small and Medium-Sized...
|
|
|
Sucampo Pharmaceuticals Selected as a Finalist for Scrip Awards 2008 Pharma Company of the Year - Small and Me
harmaceuticals, Inc.(NASDAQ:SCMP), a leading international biopharmaceutical company, today announced that it has been selected as a finalist for the Scrip Awards 2008 Pharma Company of the Year -- Small and Medium-Sized Enterprises Award...
|
|
|
Sucampo Pharmaceuticals Selected as a Finalist for Scrip Awards 2008 Pharma Company of the Year EUR' Small an
Being selected as a finalist for Scrip Awards 2008 Pharma Company of the Year in this category, after AMITIZA was a finalist for the 2006 Scrip Awards Best New Small Molecule, reflects our efforts to achieve significant business milestones...
|
|
|
Sucampo Pharmaceuticals Selected as a Finalist for Scrip Awards 2008 Pharma Company of the Year - Small and Me
BETHESDA, MD--(BUSINESS WIRE)-- Sucampo Pharmaceuticals, Inc.(NASDAQ: SCMP), a leading international biopharmaceutical company, today announced that it has been selected as a finalist for the Scrip Awards 2008 Pharma Company of the Year -...
|
|
|
Holiday Season Brings New Hope to Millions Who Suffer from Common Chronic Health Disorder
British Medical Journal study finds natural, less expensive treatments are effective for Irritable Bowel Syndrome Sufferers PRINCETON, N.J., Dec.2 /PRNewswire/ -- With its feasts, travel and family gatherings, the holiday...
|
|
|
Holiday Season Brings New Hope to Millions Who Suffer from Common Chronic Health Disorder
British Medical Journal study finds natural, less expensive treatments are effective for Irritable Bowel Syndrome Sufferers PRINCETON, N.J., Dec.2 /PRNewswire/ -- With its feasts, travel and family gatherings, the holiday...
|
|
|
Holiday Season Brings New Hope to Millions Who Suffer from Common Chronic Health Disorder
British Medical Journal study finds natural, less expensive treatments are effective for Irritable Bowel Syndrome Sufferers PRINCETON, N.J., Dec.2 /PRNewswire/ -- With its feasts, travel and family gatherings, the holiday...
|
|
|
High Growth Reported for the World Pharmaceuticals Market Brief
NEW YORK-- (BUSINESS WIRE) -- Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.The global outlook series on Pharmaceuticals provides a collection of...
|
|
|
Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
PRNewswire-FirstCall/ -- Pharmos Corporation today announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology formulated with 3% Diclofenac Diethanolamine.The multi-center, randomized,...
|
|
|
Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
Study did not achieve statistical significance ISELIN, N.J., Nov.19 /PRNewswire-FirstCall/ -- Pharmos Corporation today announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology...
|
|
|
Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
Study did not achieve statistical significance ISELIN, N.J., Nov.19 /PRNewswire-FirstCall/ -- Pharmos Corporation today announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology...
|
|
|
Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
Study did not achieve statistical significance ISELIN, N.J., Nov.19 /PRNewswire-FirstCall/ -- Pharmos Corporation today announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology...
|
|
|
Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
Study did not achieve statistical significance ISELIN, N.J., Nov.19 /PRNewswire-FirstCall/ -- Pharmos Corporation today announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology...
|
|
|
High Growth Reported for the World Pharmaceuticals Market Brief
- Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.http://www.reportlinker.com/p097881/World-Pharmaceuticals-Market-Brief.html The global outlook...
|
|
|
High Growth Reported for the World Pharmaceuticals Market Brief
- Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.http://www.reportlinker.com/p097881/World-Pharmaceuticals-Market-Brief.html The global outlook...
|
|
|
High Growth Reported for the World Pharmaceuticals Market Brief
High Growth Reported for the NEW YORK--(BUSINESS WIRE)--Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.http://www.reportlinker.com/p097881/World...
|
|
|
High Growth Reported for the World Pharmaceuticals Market Brief
-Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.World Pharmaceuticals Market Brief http://www.reportlinker.com/p097881/World-Pharmaceuticals...
|
|
|
High Growth Reported for the World Pharmaceuticals Market Brief
NEW YORK (Business Wire) -- Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.World Pharmaceuticals Market Brief http://www.reportlinker.com/p097881...
|
|
|
Irritable Bowel Syndrome May Respond to Fiber, Peppermint Oil, Antispasmodics
_ Irritable Bowel Syndrome May Respond to Fiber, Peppermint Oil, Antispasmodics.
|
|
|
Peppermint Oil, Fiber Can Fight Irritable Bowel
THURSDAY, Nov.13 (HealthDay News) -- For some patients, the best therapy for irritable bowel syndrome (IBS) may be older, cheaper drugs such as fiber, antispasmodics and peppermint oil, a new study finds. According to researchers,...
National Womens Health Information Center:
Nov 14 2008 6:17AM
Matching: irritable bowel
|
Find similar documents
|
|
|
|
This Global Strategic Business Report on Pharmaceuticals is Now Available
- Research and Markets (http://www.researchandmarkets.com/research/c2deba/pharmaceuticals) has announced the addition of the 'Pharmaceuticals - Global Strategic Business Report' report to their offering.The global outlook series on...
|
|
|
I Am Doing the Best That I Can!: Living With Inflammatory Bowel Disease and/or Irritable Bowel Syndrome (Part
Fletcher P et al.- This research enables women to share their experiences concerning their coping strategies used in the management of IBD and/or IBS. The qualitative nature of this study provides the 'voice' of women who have a GI...
|
